Sandra Parra

Dr. Sandra Parra

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2004 in Circulation
Verified
Journal Article
Closed access
Gerard AragonèsGerard Aragonès
Gerard Aragonès
BCBlai Coll
Blai Coll
SPSandra Parra
Sandra Parra
MMManuel Montero
Manuel Montero
NCNahum Calvo
Nahum Calvo
LMLluis Masana
Lluis Masana
Background— Patients infected with HIV present with premature atherosclerosis, and the 2 diseases share common pathogenic pathways. We investigated mutations in the monocyte chemoattractant protein-1 (MCP-1) and CCR-2 genes, which are known to control aspects of these pathways, to ascertain whether they are involved in atherogenesis in these patients. Methods and Results— We performed carotid and femoral artery ultrasonography to detect subclinical atherosclerosis in patients infected with HIV (n=183). MCP-1–2518G and CCR-2 64I polymorphisms were determined in the HIV group and in a population-based control group (n=348). We also determined MCP-1 circulating levels in the HIV group. The presence of MCP-1–2518G in the group of patients with subclinical atherosclerosis was significantly higher than in patients without atherosclerotic lesions (47.5% versus 18.2%, respectively; P <0.001). Furthermore, the patients with atherosclerotic lesions had higher MCP-1 plasma concentrations than did patients without lesions (74.15 [4.03] versus 57.81 [3.67] pg/mL, respectively; P =0.03). When adjusted for known cardiovascular risk factors, the MCP-1–2518G allele was associated with subclinical atherosclerosis (OR 5.72, 95% CI 1.74 to 18.80, P =0.004). Compared with measurements conducted ≈2.5 years earlier in a subset of 40 patients, intima-media thickness (IMT) in the carotid artery progressed at a mean rate of 0.06 mm/y more rapidly in patients bearing the MCP-1-mutated allele ( P =0.08). Conclusions— HIV-infected patients with the MCP-1–2518G allele have a 5-fold increased risk for atherosclerosis, as assessed by ultrasonography.

1 March 2010 in HIV Medicine
Verified
Journal Article
Closed access
SPSandra Parra
Sandra Parra
BCB Coll
B Coll
Gerard AragonèsGerard Aragonès
Gerard Aragonès
JMJ Marsillach
J Marsillach
RBR Beltrán
R Beltrán
JCJ Camps
J Camps

1 September 2007 in Atherosclerosis
Verified
Journal Article
Closed access
SPSandra Parra
Sandra Parra
Gerard AragonèsGerard Aragonès
Gerard Aragonès
BCBlai Coll
Blai Coll
NFNatalia Ferré
Natalia Ferré
JMJudit Marsillach
Judit Marsillach
JCJordi Camps
Jordi Camps

1 September 2007 in Stroke
Verified
Journal Article
Open access
PDF file
BCBlai Coll
Blai Coll
SPSandra Parra
Sandra Parra
Gerard AragonèsGerard Aragonès
Gerard Aragonès
Gerard AragonèsGerard Aragonès
Gerard Aragonès
MMManuel Montero
Manuel Montero
LMLluis Masana
Lluis Masana
Background and Purpose— The initial steps of atherosclerosis and the entry of HIV into the cell share similar biological mechanisms. Therefore, our hypothesis is that the progression of atherosclerosis in patients with HIV infection can be influenced by variations in genes implicated in both processes. Methods and Results— The progression of atherosclerosis over a 2-year follow-up period was measured as the combined carotid and femoral intima media thickness (IMT) in 141 patients with HIV infection. The ΔIMT (IMT follow-up −IMT baseline ) values were used to segregate patients as minimal progressors or regressors (lowest ΔIMT tertile), slow progressors (mid ΔIMT tertile), and rapid progressors (highest ΔIMT tertile). Mutations CCR-5Δ32, CCR-2 64I, MCP-1-2518G, SDF1-3′A, and CX3CR-1 (T280 mol/L and V249I) in the host DNA were determined. Mean age of the patients was 38.96 (SEM: 0.61) and 68.8% were male. The mean ΔIMT was 0.045 mm (0.01) per year, which represented a significant progression ( P <0.001) with respect to baseline values. Patients with minimal progression or regression had a significantly ( P =0.01) higher CD4 cell count than slow progressors and rapid progressors. Multivariate analyses indicated that age and total cholesterol were positively associated with IMT progression. In contrast, the CD4 cell count, the SDF1-3′A, and the CX3CR-1 249 I mutated alleles were associated with lesser IMT progression. Conclusion— The course of atherosclerosis in patients with HIV infection is influenced by polymorphisms in the SDF1 and CX3CR1 genes by metabolic variables and by the CD4 cell count. These data would be of help in assessing therapeutic needs of these patients.

1 August 2006 in AIDS
Verified
Journal Article
Closed access
BCBlai Coll
Blai Coll
Gerard AragonèsGerard Aragonès
Gerard Aragonès
SPSandra Parra
Sandra Parra
Gerard AragonèsGerard Aragonès
Gerard Aragonès
LMLluis Masana
Lluis Masana
We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.

1 October 2006 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
MGMontse Guardiola
Montse Guardiola
RFRaimon Ferré
Raimon Ferré
JSJuliana Salazar
Juliana Salazar
Gerard AragonèsGerard Aragonès
Gerard Aragonès
BCBlai Coll
Blai Coll
JRJosep Ribalta
Josep Ribalta
Background: Hyperlipidemia associated with the protease inhibitor (PI) component of highly active antiretrovial treatment can lead to accelerated atherosclerosis. The apolipoprotein A-V (APOA5) gene, which affects VLDL production and lipolysis, may play a role in PI-induced hyperlipidemia, particularly in individuals with the APOA5–1131T→C genotype.